Endometrial cancer is the most common malignancy of the female genital tract and the seventh most common cause of cancer death in women in Western countries ([@bib23]). The histological type and grade of endometrial cancer and the depth of myometrial invasion are prognostic factors in early-stage disease as well as risk factors for lymph-node (LN) metastasis. However, the prognostic relevance of assessing LN status by lymphadenectomy is debated. Lymphadenectomy may be omitted in patients in low- and intermediate-risk groups, while pelvic and para-aortic lymphadenectomy is recommended in patients in high-risk groups, including patients with stage IB grade 3 endometrioid cancers and type II endometrial cancer. To provide evidence-based and individualised predictions, we developed a nomogram to predict LN status for endometrial cancer by combining selected clinical and pathological risk factors using a multivariate model ([@bib3]). This nomogram was based on five clinical and pathological characteristics to predict LN metastasis. It was developed using data from the Surveillance, Epidemiology and End Results (SEER) database and has been validated externally on a validation set. In both the training and the validation sets, a conventional histopathological examination was performed to assess LN metastases, and it is likely that only macrometastases were detected ([@bib7]).

The results of a prospective multicenter study suggest that sentinel LN (SLN) biopsy could provide a trade-off between systematic lymphadenectomy and no dissection in patients with low-risk and intermediate-risk endometrial cancer ([@bib2]). Ultrastaging of LN, using serial sectioning and immunohistochemistry (IHC), is an important focus of the sentinel-node concept ([@bib7]). In this study, almost half of patients with positive SLNs had occult metastases, including micrometastases and submicrometastases, which were not detected by conventional histology. The impact of micrometastases on the prognosis and the risk of recurrence has been shown in breast cancer ([@bib12]; [@bib7]). A case--control study in women with endometrial cancer showed that removal of micrometastases was associated with a significant increase in disease-free survival ([@bib25]). Predictive factors of micrometastasis are unknown. Therefore, the predictive ability of a nomogram is also lacking. Additionally, such data could potentially be used as a surrogate to demonstrate the relative staging information provided by ultrastaging and micrometastasis.

The primary aim of this study was to evaluate and compare the accuracy of a nomogram when ultrastaging is performed on SLN in terms of calibration and discrimination. The secondary objective was to compare the values and distribution of nomogram scores in cases of LN micrometastasis and LN macrometastasis and in the absence of LN metastasis.

Materials and methods
=====================

Patients
--------

From 2007 to 2011, 187 women with presumed stage I--II endometrial cancer determined using the 2009 FIGO (International Federation of Gynecology and Obstetrics) classification underwent hysterectomy with bilateral salpingo-oophorectomy, pelvic SLN and systematic pelvic-node dissection at four French centres. All the women had biopsy-proven endometrial cancer.

All women gave informed written consent to the therapeutic procedures and to the analysis of data related to their malignancy in accordance with institutional guidelines and the Declaration of Helsinki. The protocol was approved by the national ethics committee (CEROG 2012-GYN-10-01).

Medical records were reviewed to determine age, tumour stage, histology, surgical procedure, and the final pelvic and para-aortic node status. Outcome was obtained from the outpatient records.

Sentinel-node procedure
-----------------------

The SLN procedure was performed for each patient. The pelvic and lower para-aortic regions were carefully inspected by laparoscopy for lymph ducts and dye uptake by LN. All blue and/or hot LNs were removed separately. After the SLN procedure, systematic pelvic transperitoneal LN dissection extending from the external iliac (and obturator nerve) to the iliac bifurcation was performed. The absence of residual pelvic or para-aortic radioactivity was verified after pelvic lymphadenectomy. In accordance with French guidelines ([@bib21]), a para-aortic lymphadenectomy was recommended if metastases were detected on intraoperative histology or after definitive histology. Systematic pelvic and para-aortic lymphadenectomy was recommended for patients with type 2 endometrial cancer (clear-cell, serous endometrial cancer and carcinosarcoma).

Histological analysis
---------------------

### Conventional analysis of LN

Non-SLNs were sectioned at 3-mm intervals and submitted for paraffin embedding. Each block was sectioned at one to three levels, depending on the size of the tissue in the block, and stained with haematoxylin and eosin (H&E). The size of LN metastases was estimated with an eyepiece micrometre. A macrometastasis was defined as a single focus of metastatic disease per LN, measuring \>2 mm.

### SLN-based ultrastaging

Ultrastaging was done for SLNs only, in accordance with a study validating the histological concept of the SLN procedure in endometrial cancer ([@bib8]). Each half-SLN was sectioned at 3-mm intervals. Each 3-mm section was analysed at four additional levels of 150 *μ*m. SLNs were examined by IHC with an anti-cytokeratin antibody cocktail (cytokeratins AE1-AE3; Dako Corporation, Glostrup, Denmark). Micrometastasis was defined as a focus of metastatic disease \<2 mm. A submicrometastasis was defined as a single focus of metastatic disease measuring \<0.2 mm, including the presence of single non-cohesive tumour cells.

Nomogram evaluation
-------------------

Recently, [@bib3] reported a nomogram to predict LN invasion in early stages of endometrial cancer. The parameters included in this nomogram were age, race, histological type (type I: endometrioid carcinoma; type II: carcinosarcoma, clear-cell or papillary serous), tumour grade and primary tumour extension (endometrium,\< or ⩾50% myometrial invasion or cervical stroma invasion). The mathematical model was developed using data from the SEER database, and the nomogram was validated on a single database that recorded patient data from four institutions.

For each patient, we calculated the score of the nomogram previously described and the probability of LN metastasis. We evaluated performance of the nomogram to predict nodal status assessed by conventional analysis of nodes and by ultrastaging.

Statistical analysis
--------------------

Data were analysed and compared using the *χ*^*2*^ test, the Fisher\'s Exact test and the Kruskal--Wallis test.

The nomogram performance was quantified with respect to discrimination and calibration. Discrimination (i.e., whether the relative ranking of individual predictions was in the correct order) was quantified with the area under (AUC) the receiver operating characteristic curve (i.e., the agreement between observed outcome frequencies and predicted probabilities), and calibration was studied with graphical representations of the relationship between the observed outcome frequencies and the predicted probabilities (calibration curves). To quantify miscalibration we used the unreliability index *U*, which is the difference in −2 log likelihood of a model with both *α* and *β* as free parameters and a model with *α*=0 and *β*=1 ([@bib17]). We also evaluated the average error (*E*~aver~) between the predictions and the observations obtained from the calibration curves. The clinical significance of the calibration is high because it reflects the accuracy of the individual predictions.

RESULTS
=======

Patient and surgical characteristics of the population
------------------------------------------------------

Patient and surgical characteristics are reported in [Table 1](#tbl1){ref-type="table"}. There were no differences between the groups regarding age, BMI or parity.

All 187 patients underwent pelvic lymphadenectomy with SLN biopsy. Most had a laparoscopy (78%). SLNs were not detected in 22 patients. Thirty-eight of the 187 patients (20%) had pelvic LN metastases, 20 had macrometastases detected by conventional histologic examination and 18 had micrometastases detected by ultrastaging procedures. Twenty-six of the 187 patients (14%) underwent para-aortic lymphadenectomy. Six of the 187 patients (3%) had associated para-aortic LN metastases. None had isolated para-aortic LN metastases. For the SLN procedure, there were no differences between the groups for the rate of SLN detected, the number of SLN present or the number of non-SLN removed.

We found a significant difference between the three groups for the rate of para-aortic lymphadenectomy (*P*\<0.0001) and the occurrence of positive para-aortic nodes (*P*=0.02).

Pathological characteristics
----------------------------

There were no differences between the groups regarding histological type, and there was a predominance of endometrioid carcinoma (88.8%) ([Table 2](#tbl2){ref-type="table"}). Comparing patients with or without LN metastasis, we observed significant differences for the final grade (*P*=0.0001) and the number of patients with lymphovascular scape invasion (*P*\<0.0001). The primary tumour invasion fell short of reaching statistical significance (*P*=0.05), but the tumour size was significantly larger in patients with micro- or macrometastases (*P*=0.02).

Accuracy of the nomogram to predict macrometastasis detected by conventional histologic analysis
------------------------------------------------------------------------------------------------

We performed discrimination and calibration analysis according to LN status and method of detection, that is, macrometastasis detected by conventional histologic analysis, and macrometastasis and micrometastases detected by ultrastaging.

For the prediction of metastases detected by conventional histopathology, the nomogram showed good discrimination with an AUC of 0.76 (95% CI 0.71--0.81) ([Figure 1](#fig1){ref-type="fig"}) and was well calibrated (average error=2.1%, maximal error=10.5%), with no statistical difference between predicted probabilities and observed proportions (*P*-value of the *U* index=0.56) ([Figure 2](#fig2){ref-type="fig"}).

Accuracy of the nomogram to predict nodal status including SLN-based ultrastaging
---------------------------------------------------------------------------------

Considering LN metastasis detected by conventional histologic analysis and ultrastaging, the nomogram showed poorer discrimination, with an AUC of 0.67 (95% CI 0.63--0.72) ([Figure 1](#fig1){ref-type="fig"}), and was less well calibrated (average error=10.9%, maximal error=15.9%) with a statistical difference between predictions and observations (*P-*value of the *U* index\<0.0001) ([Figure 2](#fig2){ref-type="fig"}).

Impact of SLN-based ultrastaging
--------------------------------

For the whole population, ultrastaging detected 10% additional metastasis. All these metastases were micrometasatasis. We studied the impact of SLN-based ultrastaging according to the risk of metastasis calculated by the nomogram ([Table 3](#tbl3){ref-type="table"}). The impact of ultrastadification was independent of the baseline risk: 9%, 8%, 11% and 11% in the four quartiles, respectively (*P*=0.97).

DISCUSSION
==========

Although micrometastases in breast cancers have been described previously, the concept of micrometastases in endometrial cancer has only recently been reported and investigated. The present study is the largest to focus on the primary tumoral characteristics in patients with micrometastasis. To better comprehend micrometastasis, we evaluated the accuracy of a nomogram designed to predict LN invasion in endometrial cancer. For the prediction of macrometastases, the nomogram showed good discrimination and was well calibrated, but for the prediction of LN metastasis detected by ultrastaging, the nomogram showed worse discrimination and was less well calibrated. The frequency of micrometastasis remained stable irrespective of the probability of LN metastasis calculated through the nomogram.

For patients with early-stage endometrial cancer, two randomized trials have shown that pelvic lymphadenectomy has no effect on overall or recurrence-free survival, and leads to a higher incidence of early and late complications ([@bib4]; [@bib13]). In the ASTEC study ([@bib13]), the risk of developing short-term major surgical complications was low in both groups, but more women in the lymphadenectomy group than in the standard surgery group developed specific complications. Moreover, more patients required blood transfusion in the lymphadenectomy group and the median length of operation was higher when lymphadenectomy was performed. Additionally, after adjuvant treatment, more women in the lymphadenectomy group than in the standard surgery group reported moderate or severe morbidity or treatment-related complications. Similarly, in the experience of [@bib4], both early and late postoperative complications occurred significantly more frequently in patients who had received pelvic systematic lymphadenectomy. In accordance with the findings of these two prospective studies showing that lymphadenectomy is not such a low morbidity procedure, we believe that an alternative to systematic pelvic lymphadenectomy in early endometrial cancer (provided by SLN or the use of a nomogram) should be considered, especially as the benefit of lymphadenectomy has not been proven.

In comparison with other studies reporting LN invasion in presumed stage I and II endometrial cancer, the rate of nearly 21% appears to be high. This difference could be explained by the fact that most other studies did not include micrometastases. For example, in the two major randomised trials concerning lymphadenectomy in endometrial cancer ([@bib4]; [@bib13]), the rates of patients with pelvic LN were 9% ([@bib13]) and 13% ([@bib4]), respectively. These rates of LN metastases were most likely underestimated. In the present study, IHC detected metastases that would have not been diagnosed with conventional histology in 18 of 187 patients (9.6%) with detected SLNs, representing 18 of 38 patients (47.4%) with metastases.

In the present study, the rate of micrometastasis is higher than in other reports ([@bib9]; [@bib20]; [@bib19]; [@bib16]). The difference is most likely explained by the methodology of screening for micrometastases. In other reports, SLN was not performed, and the whole lymphadenectomy specimen was examined for micrometastasis. For example, in McCoy\'s experience of screening for micrometastasis in 51 patients, only 151 LN paraffin blocks were obtained, whereas the mean number of LNs removed per patient was 12 ([@bib16]). Because micrometastases are usually defined as positive staining of cells \<2 mm in the greatest dimension, searching for them in all LNs removed during pelvic lymphadenectomy is hardly feasible. In accordance with a study validating the histological concept of the SLN procedure, ultrastaging was usually only performed for SLNs ([@bib8]). Cytokeratin, a constituent of the cytoskeleton of normal and malignant epithelial cells, is usually only present in tumour metastasis ([@bib14]). However, [@bib10] reported that cytokeratin-positive interstitial reticulum cells were increased in non-neoplastic inflammatory lymphadenopathies as well as neoplastic lymphadenopathies. This suggests that cytokeratin expressed in regional LNs does not always originate in neoplastic epithelial cells. In order to identify the presence of occult metastases in LNs, [@bib25] examined cytokeratin expression in cells other than tumour cells in LNs and its predictive value for recurrence in early-stage endometrial carcinoma. Cytokeratin expression was observed in 16% of LNs with unconfirmed metastasis, which were obtained from 14 of 36 patients with Stage I disease. Five of 14 patients with LNs expressing cytokeratin had recurrent disease in the pelvic cavity, while all 22 patients with unconfirmed cytokeratin expression in their LNs showed no recurrence. Multivariate analysis identified cytokeratin expression as an independent risk factor for recurrence in Stage I endometrial cancer. We share the conclusions of these authors suggesting that the immunohistochemical expression of cytokeratinin LNs with undetected metastases could be associated with occult LNs metastases.

Using a nomogram, we tried to better characterise and to compare the primary tumoral characteristics in patients with micrometastases. The nomogram we developed to predict LN metastasis in endometrial cancer is mainly based on primary tumoral characteristics (cancer grade, histologic subtype, depth of invasion, cervical involvement) and the training set was extracted from patients included in the SEER database who were treated between 1988 and 2007. In this population study, even if it is not detailed, IHC was most likely not performed systematically because the current standard for detection of endometrial LN metastasis involves H&E staining only. Our nomogram has been shown to be a good predictor of LN metastasis ([@bib3]). Interestingly, the nomogram approach permits the evaluation of the primary tumoral aggressiveness in each patient. Our results suggest that primary tumoral characteristics between patients without LN micrometastases and patients with macrometastases are significantly different. Interpretation of the frequency of micrometastases according to the nomogram probability suggests that compared with macrometastases, micrometastases may occur earlier and in tumours with lower carcinologic aggressiveness. These results suggest that micrometastasis could be an 'intermediate state\' between disease-free LN and macrometastasis. The initial study ([@bib3]) was conducted in order to develop and evaluate a nomogram to predict the LN metastatic risk for patients with presumed stage I and II endometrial cancer. In the original study, we chose not to propose a cutoff value, as the use of a nomogram permits to decide whether secondary lymphadenectomy is suitable at an individual level. However, we could investigate if a threshold could be established by focusing on the negative predictive value to build a model that discriminates a low-risk group for nodal metastasis. We believe that the most important goal for developing this model would be to obtain the best negative predictive value in order to prevent misclassifying a patient with LN metastasis.

In the present study few patients underwent para-aortic lymphadenectomy and because of comorbidities para-aortic lymphadenectomy could be omitted. We know that the expected rate of para-aortic LN mestastasis in patients with metastatic pelvic LNs can reach 30--50% ([@bib6]; [@bib15]), which is similar to our finding that 6 of the 12 patients with pelvic LN macrometastasis who underwent para-aortic lymphadenectomy had also aortic involvement. However, it is possible that we 'missed\' isolated para-aortic LN metastases but the number would be very low. Two methods can be used to assess this number:

-When considering the results of the ASTEC study ([@bib13]), 6% of patients with positive LN metastasis had para-aortic involvement. If we transpose the results of the ASTEC study to our population sample, as 20 patients had macroscopic pelvic LN metastases, one to two patient(s) could have had isolated para-aortic LN metastases.

-In the experiment by [@bib15] focusing on para-aortic dissemination in endometrial cancer, only 2% of patients with negative pelvic LNs had para-aortic metastasis. As the findings of this study are in accordance with the others involving more than a 100 patients ([@bib18]; [@bib1]; [@bib11]), we can apply this rate to our population sample. In doing so, we estimate the number of patients with isolated para-aortic LN metastases to be three.

Considering the low number of patients with isolated para-aortic LN metastases (one to three patients) in comparison with the number of patients with pelvic para-aortic LN metastases, it is unlikely that this would affect the discriminative accuracy of the nomogram to a large extent. Moreover, in the SEPAL study ([@bib24]), the incidence of para-aortic LN involvement in intermediate- and high-risk groups is only 14% and 18%, suggesting that the majority of the patients has little benefice of systematic para-aortic lymphadenectomy.

The impact of micrometastases remains debatable. Despite a favourable prognosis in patients with negative LN, up to 15% of patients experience a recurrence of disease. One hypothesis for this recurrence is the false-negative rates with current pathologic LN assessments. Interestingly, this risk of occult metastasis is independent of the baseline risk of nodal metastasis. Authors have investigated numerous ways to improve detection of LN metastasis, such as serial sectioning ([@bib22]), IHC and molecular testing, both alone or in combination ([@bib5]). Using these combination techniques in FIGO stage I--IV cancers demonstrated a detection rate of micrometastases between 0 and 20% ([@bib5]). Unfortunately, the impact of LN metastasis detected by ultrastaging has only been investigated through small case--control studies involving 50 patients or less ([@bib25]; [@bib9]; [@bib16]). The results of these studies provide contradictory conclusions on the prognostic significance of micrometastasis.

Without information on LN status, indications for adjuvant therapy are based on uterine features alone. Omitting lymphadenectomy carries a risk of inadequate staging, leading to secondary lymphadenectomy or systematic adjuvant radiotherapy. We believe SLN biopsy is a good alternative for the subgroup of patients who will not benefit from complete lymphadenectomy, which is associated with increased morbidity.

In conclusion, we founded that prediction of LN metastasis detected by conventional histopathology (macrometastasis) is feasible using a nomogram based on pathological characteristics of the hysterectomy specimen, whereas prediction of LN metastasis detected by ultrastaging on SLN (micrometastasis) is not correlated with LN involvement probability. Consequently, our results suggest that SLN biopsy should be performed for low and intermediate-risk endometrial cancers if we consider that this information modifies prognostic and adjuvant therapy. However, the prognostic significance of micrometastases needs to be evaluated more extensively in endometrial cancer.
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![Receiver operating characteristic curves of the model. Solid line (red): Receiver operating characteristic curves of the nomogram to predict macro LN metastases. AUC=0.76 (95% CI 0.71--0.81). Dotted line (blue): Receiver operating characteristic curves of the nomogram to predict micro and macro LN metastases. AUC=0.67 (95% CI 0.63--0.72). The color reproduction of this figure is available on the *British Journal of Cancer* online.](bjc201395f1){#fig1}

![Calibration of the nomogram to predict metastatic lymph node involvement. The horizontal axis represents the predicted probability of metastatic lymph nodes, and the vertical axis represents the actual probability of metastatic lymph nodes. Perfect prediction would correspond to the 45° broken line. Solid line (red): Calibration of the nomogram to predict macrometastatic LN involvement. The horizontal axis represents the predicted probability of macrometastatic LNs, and the vertical axis represents the actual probability of macrometastatic LNs. Perfect prediction would correspond to the 45° dashed line. Average error=2.1%, maximal error=10.5%. Dotted line (blue): Calibration of the nomogram to predict micro- and macrometastatic LN involvement. The horizontal axis represents the predicted probability of micro- and macrometastatic LNs, and the vertical axis represents the actual probability of micro- and macrometastatic LNs. Average error=10.9%, maximal error=15.9%. The color reproduction of this figure is available on the *British Journal of Cancer* online.](bjc201395f2){#fig2}

###### Patients\' and surgical characteristics

                                          **Patients without LN invasion (*****N*****=149)**   **Patients with LN micrometastases (*****N*****=18)**   **Patients with LN macrometastases (*****N*****=20)**  ***P***
  -------------------------------------- ---------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ---------
  Age (years)                                                  64.8±9.7                                              68.0±10.5                                               64.1±5.9                         0.57
  BMI (kg m^−2^)                                              27.5±10.3                                              26.0±8.4                                                26.9±9.8                         0.73
  Parity                                                       1.8±1.4                                                2.1±1.3                                                 1.2±1.2                         0.09
  SLN detected                                                131 (88%)                                              18 (100%)                                               16 (80%)                         0.16
  Number of SLNs detected                                      2.3±1.7                                                2.9±1.7                                                 2.8±0.4                         0.13
  Number of non-SLNs removed                                   11.5±5.5                                              12.8±7.7                                                13.7±9.4                         0.82
  **Surgical route**                                                                                                                                                                                          
  Laparoscopy                                                 117 (79%)                                              16 (89%)                                                12 (60%)                         0.09
  Open surgery and laparoconversion                            32 (21%)                                               2 (11%)                                                 8 (40%)                          
  Para-aortic lymphadenectomy                                  11 (7%)                                                3 (17%)                                                12 (60%)                         \<0.001
  Number of para-aortic LNs removed                            12.5±4.0                                              16.7±6.8                                                12.5±7.7                         0.42
  Positive para-aortic lymphadenectomy                            0                                                      0                                                   6 (30.0%)                        0.02

Abbreviations: BMI=body mass index; LN=lymph node; SLN=sentinel lymph node.

###### Pathological characteristics

                                                             **Patients without LN invasion (*****N*****=149)**   **Patients with LN micrometastases (*****N*****=18)**   **Patients with LN macrometastases (*****N*****=20)**  ***P***
  --------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ----------
  **Final histology[a](#t2-fn1){ref-type="fn"}**                                                                                                                                                                                 
  Endometrioid                                                                   135 (91%)                                              16 (89%)                                                15 (75%)                          
  Clear-cell                                                                      10 (7%)                                                1 (6%)                                                  2 (10%)                         0.13
  Papillary serous                                                                 4 (3%)                                                1 (6%)                                                  3 (15%)                          
  **Final grade[a](#t2-fn1){ref-type="fn"}**                                                                                                                                                                                     
  1                                                                               80 (54%)                                               9 (50%)                                                 2 (10%)                          
  2                                                                               50 (34%)                                               6 (33%)                                                 7 (35%)                         \<0.0001
  3                                                                               19 (13%)                                               3 (17%)                                                11 (55%)                          
  **Primary tumour extension[a](#t2-fn1){ref-type="fn"}**                                                                                                                                                                        
  Endometrium                                                                     25 (17%)                                               1 (6%)                                                  2 (10%)                          
  ⩽50% Myometrial invasion                                                        65 (44%)                                               7 (39%)                                                 4 (20%)                         0.05
  \>50% Myometrial invasion                                                       52 (35%)                                              10 (56%)                                                14 (70%)                          
  Cervical stromal invasion                                                        7 (5%)                                                   0                                                       0                             
  Lymphovascular space invasion                                                 28/141 (20%)                                           7/17 (41%)                                              13/19 (68%)                       \<0.0001
  Tumour size (mm)                                                               32.1±17.0                                              37.7±15.8                                               46.0±20.2                        0.02

Abbreviation: LN=lymph node.

On the hysterectomy specimen.

###### Actual probability of LN micro- and macrometastasis according to the probability of LN metastasis given by the nomogram

                                                 **Whole population**   **1st quartile**   **2nd quartile**   **3rd quartile**   **4th quartile**
  --------------------------------------------- ---------------------- ------------------ ------------------ ------------------ ------------------
  Predicted probability of LN metastasis               0.5--50%               ⩽2%               3--4%              5--14%           \> or =15%
  N                                                      187                   54                 39                 38                 56
  Mean predicted probability of LN metastasis             9%                   1%                 4%                 9%                22%
  Observed probability of LN macrometastasis         20/187 (11%)          1/54 (2%)          2/39 (5%)          4/38 (11%)        13/56 (23%)
  Observed probability of LN micrometastasis         18/187 (10%)          5/54 (9%)          3/39 (8%)          4/38 (11%)         6/56 (11%)

Abbreviation: LN=lymph node.

[^1]: co-senior author.
